|Bid||40.66 x 2200|
|Ask||40.67 x 5800|
|Day's Range||40.40 - 40.69|
|52 Week Range||37.20 - 44.54|
|PE Ratio (TTM)||40.42|
|Dividend & Yield||1.99 (4.97%)|
|1y Target Est||N/A|
The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. The FDA's decision is in keeping with an advisory panel's recommendation in August that the FDA reject the drug. "We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab," He added that the company is seeking to "gain a full understanding of FDA requirements for U.S. approval" and plans to have a follow-up discussion with the agency.
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.